ERK 5/MAPK pathway has a major role in 1α,25-(OH)2 vitamin D3-induced terminal differentiation of myeloid leukemia cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 144, Issue PART A, 2014, Pages 223-227

  Wang, Xuening ^a   Pesakhov, Stella ^b   Weng, Ashley ^a   Kafka, Michael ^b   Gocek, Elzbieta ^b   Nguyen, Mai ^a   Harrison, Jonathan S ^c   Danilenko, Michael ^b   Studzinski, George P ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Acute myeloid leukemia (AML); Cell differentiation; ERK1 2; ERK5; MAPK inhibitors; Vitamin D derivatives

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BIX 02189; CD11B ANTIGEN; CD14 ANTIGEN; COLECALCIFEROL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; XMD 8 92; CALCITRIOL; MITOGEN ACTIVATED PROTEIN KINASE 7 INHIBITOR; PROTEIN KINASE INHIBITOR; VITAMIN D DERIVATIVE; XMD 892;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER CENTER; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN EXPRESSION; REVIEW; WESTERN BLOTTING; CELL CYCLE ARREST; CELL CYCLE PHASE; MYELOID LEUKEMIA; PHASE TRANSITION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ACUTE MYELOID LEUKEMIA (AML); CELL DIFFERENTIATION; ERK1/2; ERK5; MAPK INHIBITORS; VITAMIN D DERIVATIVES;

ANIMALS; CALCITRIOL; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID; MITOGEN-ACTIVATED PROTEIN KINASE 7; MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; VITAMINS;

EID: 84906789767     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.10.002     Document Type: Review

References (13)

1. E. Abe, C. Miyaura, H. Sakagami, M. Takeda, K. Konno, T. Yamazaki, S. Yoshiki, and T. Suda Differentiation of mouse myeloid leukemia cells induced by 1a,25-dihydroxyvitamin D3 Proc. Natl. Acad. Sci. U.S.A. 78 1981 4990 4994
2. G.P. Studzinski, A.K. Bhandal, and Z.S. Brelvi A system for monocytic differentiation of leukemic cells HL 60 by a short exposure to 1,25-dihydroxycholecalciferol Proc. Soc. Exp. Biol. Med. 179 1985 288 295
3. 3 with two side chains: interaction with its nuclear receptor and cellular actions J. Med. Chem. 43 2000 2719 2730
4. J.S. Harrison, and A. Bershadskiy Clinical experience using vitamin d and analogs in the treatment of myelodysplasia and acute myeloid leukemia: A review of the literature Leuk. Res. Treat. 2012 2012 125814
5. C. Fremin, and S. Meloche From basic research to clinical development of MEK1/2 inhibitors for cancer therapy J. Hematol. Oncol. 3 2010 8
6. G.N. Nithianandarajah-Jones, B. Wilm, C.E. Goldring, J. Muller, and M.J. Cross ERK5: structure, regulation and function Cell. Signal. 24 2012 2187 2196
7. J.C. Montero, A. Ocana, M. Abad, M.J. Ortiz-Ruiz, A. Pandiella, and A. Esparis-Ogando Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target PLoS ONE 4 2009 e5565
8. X. Wang, E. Gocek, V. Novik, J.S. Harrison, M. Danilenko, and G.P. Studzinski Studzinski, inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D3 Cell Cycle 9 2010 4542 4551
9. R.J. Tatake, M.M. O'Neill, C.A. Kennedy, A.L. Wayne, S. Jakes, D. Wu, S.Z. Kugler Jr., M.A. Kashem, P. Kaplita, and R.J. Snow Identification of pharmacological inhibitors of the MEK5/ERK5 pathway Biochem. Biophys. Res. Commun. 377 2008 120 125
10. Q. Yang, X. Deng, B. Lu, M. Cameron, C. Fearns, M.P. Patricelli, J.R. Yates 3rd, N.S. Gray, and J.D. Lee Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein Cancer Cell 18 2010 258 267
11. T. Erazo, A. Moreno, G. Ruiz-Babot, A. Rodriguez-Asiain, N.A. Morrice, J. Espadamala, J.R. Bayascas, N. Gomez, and J.M. Lizcano Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex Mol. Cell. Biol. 33 2013 1671 1686
12. Q.M. Wang, J.B. Jones, and G.P. Studzinski Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells Cancer Res. 56 1996 264 267
13. 3 leads to the induced differentiation of the myelomonocytic cell line U937 Genes Dev. 10 1996 142 153